-
Something wrong with this record ?
Európa schválila nové perorálne podávané lieky – dimetylfumarát a teriflunomid na liečbu sclerosis multiplex [Europe approves new oral drugs for the treatment of sclerosis multiplex-dimethyl fumarate and teriflunomid]
Zuzana Baťová, Jana Klimasová
Language Slovak Country Slovakia
Výbor pre humánne lieky (CHMP) pri Európskej liekovej agentúre odporučil v marci 2013 registráciu dvoch nových liečiv teriflunomidu (Aubagio tablety) a dimetylfumarátu (Tecfidera kapsuly) na liečbu relaps remitujúcej formy sclerosis multiplex. Teriflunomid je selektívny imunosupresant s protizápalovými účinkami. Dimetylfumarát aktivuje signálnu kaskádu nukleárneho faktora. Nakoľko ide o nové perorálne formy, očakáva sa pozitívny vplyv na komplianciu pacientov.
In march 2013, the Committee for Medicinal Product for Human Use (CHMP) at European Medicines Agency adopted a positive opinion, recommending the granting of marketing authorisation for two new medicines – dimethyl fumarate (Aubagio) and teriflunomide (Tecfidera) for the treatment of relaps remitting form of multiple sclerosis. Teriflunomide is selective immunosuppressant with anti-inflammatory properties. Dimethyl fumarate primarily acts by triggering the activation of the Nuclear factor transcriptional pathway. These are the new oral formulations which should increase patients´ compliance.
Europe approves new oral drugs for the treatment of sclerosis multiplex-dimethyl fumarate and teriflunomid
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14053966
- 003
- CZ-PrNML
- 005
- 20150617162656.0
- 007
- ta
- 008
- 140402s2013 xo f 000 0|slo||
- 009
- AR
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a slo
- 044 __
- $a xo
- 100 1_
- $a Baťová, Zuzana $7 xx0195384
- 245 10
- $a Európa schválila nové perorálne podávané lieky – dimetylfumarát a teriflunomid na liečbu sclerosis multiplex / $c Zuzana Baťová, Jana Klimasová
- 246 31
- $a Europe approves new oral drugs for the treatment of sclerosis multiplex-dimethyl fumarate and teriflunomid
- 520 3_
- $a Výbor pre humánne lieky (CHMP) pri Európskej liekovej agentúre odporučil v marci 2013 registráciu dvoch nových liečiv teriflunomidu (Aubagio tablety) a dimetylfumarátu (Tecfidera kapsuly) na liečbu relaps remitujúcej formy sclerosis multiplex. Teriflunomid je selektívny imunosupresant s protizápalovými účinkami. Dimetylfumarát aktivuje signálnu kaskádu nukleárneho faktora. Nakoľko ide o nové perorálne formy, očakáva sa pozitívny vplyv na komplianciu pacientov.
- 520 9_
- $a In march 2013, the Committee for Medicinal Product for Human Use (CHMP) at European Medicines Agency adopted a positive opinion, recommending the granting of marketing authorisation for two new medicines – dimethyl fumarate (Aubagio) and teriflunomide (Tecfidera) for the treatment of relaps remitting form of multiple sclerosis. Teriflunomide is selective immunosuppressant with anti-inflammatory properties. Dimethyl fumarate primarily acts by triggering the activation of the Nuclear factor transcriptional pathway. These are the new oral formulations which should increase patients´ compliance.
- 653 00
- $a sclerosis multiplex, teriflunomid, dimetyfumarát
- 653 00
- $a sclerosis multiplex, teriflunomide, dimethyl fumarate
- 700 1_
- $a Klimasová, Jana $u -
- 773 0_
- $w MED00152243 $t Neurológia $x 1336-8621 $g Roč. 8, č. 2 (2013), s. 98-100
- 856 41
- $u http://samedi.sk/?page=archiv&act=Archiv_clanok&identif=neurológia&clanok_id=232 $y SAMEDI.sk
- 910 __
- $a ABA008 $b B 2465 $c 604 $y - $z 0
- 990 __
- $a 20140402 $b ABA008
- 991 __
- $a 20150617163052 $b ABA008
- 999 __
- $a ok $b bmc $g 1020827 $s 852546
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 8 $c 2 $d 98-100 $i 1336-8621 $m Neurológia $x MED00152243
- LZP __
- $a Samedi-retro-20140402
